Cargando…

A patient with acquired hemophilia A induced by clopidogrel

Acquired hemophilia A (AHA) is a rare bleeding disorder caused by autoantibodies against factor VIII (FVIII). Treatment with clopidogrel is a cause of AHA, but its clinical course is unknown. Recently, we treated a 65-year-old man who was hospitalized for cerebellar infarction and had a prolonged ac...

Descripción completa

Detalles Bibliográficos
Autores principales: Hwang, Hye Won, Kong, Jee Hyun, Yu, Dong Wook, Kim, Woo Taek, Kim, Hyun Soo, Lee, Chong In
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3317479/
https://www.ncbi.nlm.nih.gov/pubmed/22479283
http://dx.doi.org/10.5045/kjh.2012.47.1.80
_version_ 1782228561435820032
author Hwang, Hye Won
Kong, Jee Hyun
Yu, Dong Wook
Kim, Woo Taek
Kim, Hyun Soo
Lee, Chong In
author_facet Hwang, Hye Won
Kong, Jee Hyun
Yu, Dong Wook
Kim, Woo Taek
Kim, Hyun Soo
Lee, Chong In
author_sort Hwang, Hye Won
collection PubMed
description Acquired hemophilia A (AHA) is a rare bleeding disorder caused by autoantibodies against factor VIII (FVIII). Treatment with clopidogrel is a cause of AHA, but its clinical course is unknown. Recently, we treated a 65-year-old man who was hospitalized for cerebellar infarction and had a prolonged activated partial thromboplastin time (aPTT) with soft tissue oozing after 3 weeks of clopidogrel use. We terminated clopidogrel administration and transfused the patient with fresh frozen plasma. However, the aPTT increased up to 98.8 seconds, and the FVIII and FVIII inhibitor levels were <1% and 5.4 Bethesda units/mL, respectively. Clopidogrel-associated AHA was considered, and we began steroid treatment. Two months later, FVIII, FVIII inhibitor, and aPTT values were normalized. No further bleeding or aPTT prolongation has been reported during the 2-year follow-up period. AHA should be considered in patients taking clopidogrel and experiencing bleeding, unless the platelet count and coagulation screen are normal.
format Online
Article
Text
id pubmed-3317479
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis
record_format MEDLINE/PubMed
spelling pubmed-33174792012-04-04 A patient with acquired hemophilia A induced by clopidogrel Hwang, Hye Won Kong, Jee Hyun Yu, Dong Wook Kim, Woo Taek Kim, Hyun Soo Lee, Chong In Korean J Hematol Case Report Acquired hemophilia A (AHA) is a rare bleeding disorder caused by autoantibodies against factor VIII (FVIII). Treatment with clopidogrel is a cause of AHA, but its clinical course is unknown. Recently, we treated a 65-year-old man who was hospitalized for cerebellar infarction and had a prolonged activated partial thromboplastin time (aPTT) with soft tissue oozing after 3 weeks of clopidogrel use. We terminated clopidogrel administration and transfused the patient with fresh frozen plasma. However, the aPTT increased up to 98.8 seconds, and the FVIII and FVIII inhibitor levels were <1% and 5.4 Bethesda units/mL, respectively. Clopidogrel-associated AHA was considered, and we began steroid treatment. Two months later, FVIII, FVIII inhibitor, and aPTT values were normalized. No further bleeding or aPTT prolongation has been reported during the 2-year follow-up period. AHA should be considered in patients taking clopidogrel and experiencing bleeding, unless the platelet count and coagulation screen are normal. Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2012-03 2012-03-28 /pmc/articles/PMC3317479/ /pubmed/22479283 http://dx.doi.org/10.5045/kjh.2012.47.1.80 Text en © 2012 Korean Society of Hematology http://creativecommons.org/licenses/by-nc/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Hwang, Hye Won
Kong, Jee Hyun
Yu, Dong Wook
Kim, Woo Taek
Kim, Hyun Soo
Lee, Chong In
A patient with acquired hemophilia A induced by clopidogrel
title A patient with acquired hemophilia A induced by clopidogrel
title_full A patient with acquired hemophilia A induced by clopidogrel
title_fullStr A patient with acquired hemophilia A induced by clopidogrel
title_full_unstemmed A patient with acquired hemophilia A induced by clopidogrel
title_short A patient with acquired hemophilia A induced by clopidogrel
title_sort patient with acquired hemophilia a induced by clopidogrel
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3317479/
https://www.ncbi.nlm.nih.gov/pubmed/22479283
http://dx.doi.org/10.5045/kjh.2012.47.1.80
work_keys_str_mv AT hwanghyewon apatientwithacquiredhemophiliaainducedbyclopidogrel
AT kongjeehyun apatientwithacquiredhemophiliaainducedbyclopidogrel
AT yudongwook apatientwithacquiredhemophiliaainducedbyclopidogrel
AT kimwootaek apatientwithacquiredhemophiliaainducedbyclopidogrel
AT kimhyunsoo apatientwithacquiredhemophiliaainducedbyclopidogrel
AT leechongin apatientwithacquiredhemophiliaainducedbyclopidogrel
AT hwanghyewon patientwithacquiredhemophiliaainducedbyclopidogrel
AT kongjeehyun patientwithacquiredhemophiliaainducedbyclopidogrel
AT yudongwook patientwithacquiredhemophiliaainducedbyclopidogrel
AT kimwootaek patientwithacquiredhemophiliaainducedbyclopidogrel
AT kimhyunsoo patientwithacquiredhemophiliaainducedbyclopidogrel
AT leechongin patientwithacquiredhemophiliaainducedbyclopidogrel